Poly(ADP-ribosylation) processing as a target for the anti-tumor effects of the cell differentiating agent, hexamethylenebisacetamide, and the N6-substituted adenosines.
The cellular process regulating the post-translational poly(ADP-ribosylation) of various nuclear acceptor proteins is discussed in relation to its significance as a target for cancer chemotherapy; and with particular reference to the mechanism underlying the anti-tumor effects of the cell differentiating agent, hexamethylenebisacetamide. Of special note are the influences which may be exerted on tumor cells expressing certain major types of oncogenically-activated cellular proto-oncogenes (oncogenes). A basis for a pharmacological approach to tumor therapy is further proposed from considerations of the action of a class of anti-tumor agents, the N6-substituted adenosines, by reason of their possible effects on poly(ADP-ribosylation) processing, as well as on other cellular processes of relevance for tumor therapy.
Alderson
T
T
Department of Pharmacology, Cambridge University, UK.
D000081:Acetamides / Q000494:pharmacology*; D000241:Adenosine / Q000031:analogs & derivatives*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009687:Nuclear Proteins / Q000378:metabolism*; D011064:Poly Adenosine Diphosphate Ribose / Q000378:metabolism*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000187:drug effects / Q000378:metabolism; D011499:Protein Processing, Post-Translational / Q000187:drug effects*
D000081:Acetamides; D000970:Antineoplastic Agents; D009687:Nuclear Proteins; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011064:Poly Adenosine Diphosphate Ribose; D011065:Poly(ADP-ribose) Polymerases; D000241:Adenosine; C014026:hexamethylene bisacetamide